ras homolog family member DGenealiases: ARHD · RHOHP1 · RHOM · Rho
Q-omics provides the consensus-scored RHOD profile across patient tissues and cancer cell-line models. RHOD expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RHOD is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, RHOD RNA expression shows 15,607 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, LUAD, and TGCT as cancer lineages where RHOD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RHOD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RHOD survival associations across molecular data types. RHOD RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RHOD RNA expression–survival associations across cancer types. High RHOD expression shows unfavorable associations in PAAD, LGG, CESC, LUSC and UCS, but favorable associations in UVM. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RHOD RNA expression.
This table summarizes RHOD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RHOD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RHOD shows lower tumor expression in KIRC and KICH and higher tumor expression in LUAD, COAD, BLCA and LUSC. The LUAD box plot shows higher RHOD RNA expression in tumor versus normal tissue (log2 FC = +1.427, t-test p < 0.001).
This table shows molecular features associated with RHOD in patient tissues and cancer cell lines. In patient samples, RHOD shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RHOD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
